Another batch of pharmaceutical companies such as KingMed Medicine and Shanghai Yizhong disclosed semi-annual reports, most of which achieved performance growth

[Pharmaceutical Network Industry News] Recently, listed companies have intensively disclosed semi-annual reports and semi-annual performance forecasts.
At present, hundreds of pharmaceutical companies have disclosed semi-annual transcripts, and more than half of them have achieved a year-on-year increase in net profit
.

On August 18, another batch of pharmaceutical companies disclosed their semi-annual reports, including Golden Mile Medical, Shanghai Yizhong, Antu Biology, etc.
Most of them achieved growth in performance
.

According to the interim report of Huaheng Biology, the report shows that in the first half of 2022, the revenue was 629 million yuan, a year-on-year increase of 65.
65%; the net profit was 129 million yuan, a year-on-year increase of 107.
60%; the net profit attributable to shareholders of the listed company was 129 million yuan, A year-on-year increase of 107.
60%; basic earnings per share was 1.
19 yuan
.

The 2022 semi-annual report disclosed by Jinyu Medical showed that the company's revenue in the first half of the year was 8.
312 billion yuan, a year-on-year increase of 52.
37%; the net profit attributable to the parent was 1.
643 billion yuan, a year-on-year increase of 55.
11%
.

The company's main business income of medical testing reached 7.
873 billion yuan, a year-on-year increase of 51.
34%
.

 　　Shanghai Yizhong disclosed the 2022 semi-annual report.
During the reporting period, the company achieved operating income of 71.
8708 million yuan; net profit attributable to shareholders of the listed company was 60.
9792 million yuan, compared with a net profit loss of 12.
2262 million yuan in the same period last year; basic earnings per share were 0.
58 yuan
.

 　　Antu Bio's 2022 semi-annual report disclosed that the company achieved a total operating income of 2.
07 billion yuan in the first half of 2022, a year-on-year increase of 23.
4%; a net profit attributable to the parent of 534 million yuan, a year-on-year increase of 29.
3%; earnings per share was 0.
91 yuan
.

 　　Liuyao Group disclosed the 2022 semi-annual report.
In the first half of 2022, the company's sales scale continued to expand, achieving an operating income of 9.
202 billion yuan, a year-on-year increase of 10.
56%; the net profit attributable to shareholders of the listed company was 369 million yuan, a year-on-year increase of 12.
04%
.

 　　According to the 2022 semi-annual report of Kangtuo Medical, the company achieved operating income of 115 million yuan in the first half of the year, a year-on-year increase of 20.
5%; net profit attributable to the parent was 39.
1425 million yuan, a year-on-year increase of 12.
71%
.

 　　Aibo Medical released its semi-annual report.
In the first half of 2022, the company achieved revenue of 273 million yuan, a year-on-year increase of 32.
33%, and a net profit attributable to the parent of 123 million yuan, a year-on-year increase of 34.
68%
.

 　　Steady Medical announced that the company's operating income in the first half of 2022 was 5.
158 billion yuan, a year-on-year increase of 27.
05%; the net profit attributable to shareholders of the listed company was 893 million yuan, a year-on-year increase of 17.
32%
.

 　　However, there are both joys and sorrows.
The net profit performance of pharmaceutical companies such as Olin Bio, Sanyuan Bio, Jingfeng Pharmaceutical, and Yixintang in the first half of the year was somewhat unsatisfactory
.

 　　Rendu Bio’s semi-annual financial report shows that in the first half of 2022, the company’s operating income was about 170 million yuan, a year-on-year increase of 21.
07%; the net profit attributable to shareholders of the listed company was about 21.
92 million yuan, a year-on-year decrease of 33.
64%
.

 　　According to the semi-annual report of Oulin Bio, the company achieved operating income of 233 million yuan in the first half of the year, a year-on-year increase of 37.
6%; net profit attributable to the parent was 31.
0424 million yuan, a year-on-year decrease of 26.
71%
.

 　　According to the semi-annual report of Sanyuan Bio, in the first half of the year, the operating income was 457 million yuan, down 41.
89% year-on-year; the net profit attributable to the parent was 119 million yuan, down 50.
93% year-on-year
.

 　　Jingfeng Pharmaceutical released a performance forecast for the semi-annual report.
The company expects that the net profit attributable to shareholders of listed companies from January to June 2022 will be -13.
30 million to -10.
25 million, a year-on-year change of -115.
87% to -112.
23%.
Yixintang semi-annual report shows that the first half of the year will achieve The total operating income was 7.
965 billion yuan, a year-on-year increase of 18.
85%; the net profit attributable to the parent was 418 million yuan, a year-on-year decrease of 20.
16%
.

 　　From the perspective of companies with good performance, they are mainly concentrated in the fields of testing and medical care, and they are in a relatively high prosperity track
.

The decline in performance of pharmaceutical companies is mainly due to the impact of factors such as the epidemic, and related companies have been severely tested at the operational level
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.